Clinical Trial Search

Primary: Number of Participants In Intent to Treat (ITT) Analysis Set With Superficial and Deep Incisional Surgical Site Infections (SSI) Involving Principal Incision Within 30…

Primary: Overall Survival — 4.1; 6.6 months — p=0.07

Primary: Percentage of Participants With Adverse Events — 100; 95.7 Percentage of participants

Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib) — 17.2; 27.6; 31.5 percentage of participants — p=0.071

Primary: Number of Days Until Alleviation of Flu Symptoms Post Treatment — 5.3; 4.9 days

Primary: Percentage of Positive-Pressure Ventilation Inflations Between 4 - 8 Mls/kg — 30.2; 30.7 percentage of inflations — p=0.896

Primary: Adverse Events (AEs) and Serious Adverse Events (SAEs) in a Passive ROM Exercise Program, Administered up to 21 Days After the Norwood Procedure, in Infants With Single…

Primary: Part-2 (Disease Progression): Time to First Treatment Failure — NA; NA days

Primary: Allogenic Blood Transfusion Rates — 21; 13 Participants

Primary: Overall Survival — 7.23; 6.21 month — p=0.032

Primary: Ventilation Distribution as Measured by Ventilation Defect+Low Percent — 57.8; 52.5 percentage of total ventilation — p=0.006

Primary: Blood Volume Loss — 2274; 2407 milliliters

Primary: Treatment-related Mortality (TRM) — 3; 3; 7; 3 Percentage of Participants — p=0.9

Primary: Total Spinal Cord Independence Measure, Version III (SCIM III) Score Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury…

Primary: Percent Change in Body Weight From Baseline to Day 59 — -1.40; -3.98 Percent change in body weight — p=0.011